EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer



RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer



Oncology Reports 31(4): 1661-1668



To better understand the role of the N-Terminal Ras association domain family (RASSF) genes in the development of gastric cancer, we examined the expression of RASSF7 and RASSF10 and RASSF10 methylation in gastric cancer. We found that RASSF10 expression was lost in six gastric cancer cell lines, and was rescued by a DNA demethylating agent and a histone deacetylase inhibitor. However, RASSF7 expression was strong in four cancer cell lines as well as in 87% of primary gastric cancer tissues. In contrast, RASSF7 expression was moderate in the GES-1 cell line and negative in 33.3% of the corresponding non-cancerous tissues. Analysis of RASSF10 methylation by methylation-specific PCR (MSP) and sequencing revealed that the methylation frequency in primary gastric carcinoma tissues was significantly higher compared to that in adjacent non-carcinoma tissues (61.6 vs. 38.4%; p<0.01). The methylation frequency in the tumor with invasion depth at T3 and T4 was significantly higher compared to that with invasion depth at T1 and T2 (67.1 vs. 37.5%; p<0.05). Hypermethylation of RASSF10 was found in the patients with lymph node metastasis, compared to those with unaffected lymph nodes (68.8 vs. 40.9%; p<0.05). Among the 4 gross types of the Borrmann classification, i.e. EGC, Borrmann Ⅰ, Borrmann Ⅱ, Borrmann Ⅲ and Borrmann Ⅳ, the last one was more frequently methylated (85.7 vs. 56.9%; p<0.05). The present study revealed that RASSF10 is an epigenetically silenced gene involved in tumor invasion and metastasis in gastric cancer, suggesting that the methylation status of RASSF10 may be a useful indicator to predict the malignant degree of gastric cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333468

Download citation: RISBibTeXText

PMID: 24573726

DOI: 10.3892/or.2014.3039



Related references

RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer. Biochemical and Biophysical Research Communications 432(4): 632-637, 2013

Galanin is an epigenetically silenced tumor suppressor gene in gastric cancer cells. Plos One 13(2): E0193275-E0193275, 2018

Novel tumor-suppressor gene epidermal growth factor-containing fibulin-like extracellular matrix protein 1 is epigenetically silenced and associated with invasion and metastasis in human gastric cancer. Molecular Medicine Reports 9(6): 2283-2292, 2015

CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 76(3): 324-331, 2012

Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Research 62(9): 2455-2461, 2002

RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget 7(4): 4279-4297, 2016

Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochemical and Biophysical Research Communications 362(1): 212-217, 2007

Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5(1): 87-94, 2013

Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Human Molecular Genetics 12(17): 2209-2219, 2003

Long noncoding RNA TOB1-AS1, an epigenetically silenced gene, functioned as a novel tumor suppressor by sponging miR-27b in cervical cancer. American Journal of Cancer Research 8(8): 1483-1498, 2018

Epigenetically Silenced Candidate Tumor Suppressor Genes in Prostate Cancer: Identified by Modeling Methylation Stratification and Applied to Progression Prediction. Cancer Epidemiology, Biomarkers & Prevention 2018: -, 2018

The histone deacetylase inhibitor valproic acid restores expression of the epigenetically silenced RARbeta2 tumor suppressor gene in breast cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 44: 448, July, 2003

Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. Neuro-Oncology 9(2): 135-144, 2007

NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. Journal of Hepatology 45(1): 81-89, 2006

WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood 110(12): 4130-4132, 2007